+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Enbrel"

Enbrel- Drug Insight, 2019 - Product Thumbnail Image

Enbrel- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
Rheumatoid Arthritis Market and Forecast Analysis to 2025 - Product Thumbnail Image

Rheumatoid Arthritis Market and Forecast Analysis to 2025

  • Drug Pipelines
  • August 2018
  • 610 Pages
  • Global
From
Psoriatic Arthritis Market and Forecast Analysis 2035 - Product Thumbnail Image

Psoriatic Arthritis Market and Forecast Analysis 2035

  • Drug Pipelines
  • July 2018
  • 503 Pages
  • Global
From
Enbrel - Product Thumbnail Image

Enbrel

  • Report
  • May 2018
  • 61 Pages
  • Global
From
From
Loading Indicator

Enbrel is a biologic drug used to treat immune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is a recombinant fusion protein composed of the extracellular ligand-binding portion of the human 75 kDa tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. Enbrel works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Enbrel is a widely used drug in the immune disorder drug market. It is approved for use in adults and children over the age of four. It is administered as a subcutaneous injection and is available in both prefilled syringes and autoinjectors. The Enbrel market is highly competitive, with several companies offering similar products. These include Amgen, Pfizer, AbbVie, Janssen, and UCB. Show Less Read more